Immunome (NASDAQ:IMNM) Coverage Initiated by Analysts at Lake Street Capital

Equities researchers at Lake Street Capital assumed coverage on shares of Immunome (NASDAQ:IMNM) in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $23.00 price target on the stock. Lake Street Capital’s price objective points to a potential upside of 267.41% from the company’s current price.

IMNM has been the topic of several other reports. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Stephens reiterated an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Finally, Lifesci Capital started coverage on Immunome in a report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $25.14.

Immunome Stock Down 7.0 %

Shares of NASDAQ:IMNM opened at $6.26 on Wednesday. The company has a market cap of $544.31 million, a price-to-earnings ratio of -0.77 and a beta of 1.93. The business has a 50 day moving average price of $9.36 and a 200 day moving average price of $11.16. Immunome has a twelve month low of $6.19 and a twelve month high of $22.26.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The business had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. Analysts anticipate that Immunome will post -2.21 EPS for the current year.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall purchased 137,100 shares of the stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the transaction, the chief executive officer now directly owns 806,736 shares of the company’s stock, valued at approximately $5,881,105.44. The trade was a 20.47 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Philip Tsai acquired 12,300 shares of the company’s stock in a transaction on Monday, March 24th. The shares were bought at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the purchase, the chief technology officer now directly owns 33,300 shares of the company’s stock, valued at approximately $280,386. This represents a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 306,400 shares of company stock valued at $2,322,995. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several institutional investors have recently added to or reduced their stakes in IMNM. BNP Paribas Financial Markets bought a new stake in Immunome during the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new position in Immunome in the fourth quarter worth $75,000. AlphaQuest LLC grew its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after buying an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC bought a new position in shares of Immunome in the fourth quarter valued at about $95,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.